AbbVie Inc. (NYSE:ABBV) Position Decreased by O ROURKE & COMPANY Inc

O ROURKE & COMPANY Inc decreased its holdings in shares of AbbVie Inc. (NYSE:ABBVGet Rating) by 3.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,693 shares of the company’s stock after selling 110 shares during the period. O ROURKE & COMPANY Inc’s holdings in AbbVie were worth $412,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. boosted its holdings in shares of AbbVie by 19.3% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 26,538 shares of the company’s stock worth $4,064,000 after buying an additional 4,300 shares during the period. Fiduciary Group LLC boosted its holdings in shares of AbbVie by 1.6% in the second quarter. Fiduciary Group LLC now owns 24,121 shares of the company’s stock worth $3,427,000 after buying an additional 382 shares during the period. Varma Mutual Pension Insurance Co boosted its holdings in shares of AbbVie by 13.2% in the second quarter. Varma Mutual Pension Insurance Co now owns 367,306 shares of the company’s stock worth $56,256,000 after buying an additional 42,708 shares during the period. B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of AbbVie by 2.5% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 360,769 shares of the company’s stock worth $55,255,000 after buying an additional 8,837 shares during the period. Finally, TCG Advisory Services LLC boosted its holdings in shares of AbbVie by 947.5% in the second quarter. TCG Advisory Services LLC now owns 15,251 shares of the company’s stock worth $2,336,000 after buying an additional 13,795 shares during the period. Institutional investors own 68.25% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on ABBV shares. SVB Leerink decreased their target price on shares of AbbVie from $140.00 to $135.00 and set an “underperform” rating for the company in a report on Friday, September 30th. StockNews.com started coverage on shares of AbbVie in a research report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Morgan Stanley reduced their price target on shares of AbbVie from $185.00 to $178.00 and set an “overweight” rating for the company in a research report on Monday, October 31st. Piper Sandler reduced their price target on shares of AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. Finally, BMO Capital Markets reduced their price target on shares of AbbVie from $170.00 to $169.00 and set an “outperform” rating for the company in a research report on Monday, October 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $157.32.

AbbVie Stock Down 0.3 %

ABBV traded down $0.40 during midday trading on Thursday, hitting $159.39. 3,221,178 shares of the company’s stock traded hands, compared to its average volume of 6,001,301. AbbVie Inc. has a one year low of $115.10 and a one year high of $175.91. The company has a market cap of $281.88 billion, a PE ratio of 21.28, a price-to-earnings-growth ratio of 4.50 and a beta of 0.69. The company has a debt-to-equity ratio of 3.77, a current ratio of 0.93 and a quick ratio of 0.83. The stock’s fifty day simple moving average is $145.57 and its 200-day simple moving average is $145.75.

AbbVie (NYSE:ABBVGet Rating) last released its quarterly earnings results on Friday, October 28th. The company reported $3.66 EPS for the quarter, beating analysts’ consensus estimates of $3.57 by $0.09. AbbVie had a net margin of 23.19% and a return on equity of 155.88%. The company had revenue of $14.81 billion for the quarter, compared to analyst estimates of $14.95 billion. During the same quarter last year, the firm posted $3.33 earnings per share. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. As a group, equities analysts anticipate that AbbVie Inc. will post 14.01 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 15th. Stockholders of record on Friday, January 13th will be given a $1.48 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.41. The ex-dividend date is Thursday, January 12th. This represents a $5.92 dividend on an annualized basis and a dividend yield of 3.71%. AbbVie’s dividend payout ratio (DPR) is currently 75.30%.

AbbVie Profile

(Get Rating)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVGet Rating).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.